Investment firm Raymond James announced an upgrade of biopharmaceutical company Dianthus Therapeutics Inc. (DNTH) stock rating from "Outperform" to "Strong Buy".
Show original
Meanwhile, the institution has significantly raised its target price from the previous $63 to $123, demonstrating strong confidence in the company's future growth prospects.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$70,740.5
+3.29%
Ethereum
ETH
$2,055.3
+2.28%
Tether USDt
USDT
$1
+0.02%
BNB
BNB
$647.35
+2.23%
XRP
XRP
$1.4
+2.65%
USDC
USDC
$1
+0.01%
Solana
SOL
$87.01
+3.05%
TRON
TRX
$0.2849
-0.16%
Dogecoin
DOGE
$0.09635
+5.66%
Cardano
ADA
$0.2663
+3.89%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now